Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pyxis Oncology

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS SNDX
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Announces $50 Million Private Placement
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Successfully Completes Acquisition of Apexigen
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.